CEO Dongzhou Jeffery Liu describes the science behind amanitin (it is based on natural poisons, which occur in the death cap mushroom) and discusses Heidelberg Pharma's lead program, a BCMA antibody-drug conjugate, and earlier stage ones targeting CD37 and PSMA. Plus, partnerships with Takeda and Huadong Medicine.

Thomas Rückle highlights projects focused on neutrophils and multispecifics in oncology, a women's health initiative with the Gates Foundation, and an AI based project being done in partnership with the government of Barbados and with the support of the European Union.

CTO Martin Schüttler demonstrates where the device is implanted in the brain, which is different than other companies in this field, and how it is intended to work. Three patients have now tested the system at Harborview Medical Center in Seattle.

CEO Elias Paptheodorou walks us through the data and descirbes how this has already been tested (for safety) in five cancer patients who had small portions of their liver resected. The next step is to test it in patients with major resections, and also a randomized phase 2a, both of which the company already has the cash to fund.

Co-Founder & CEO Harpreet Singh walks us through the science of PRAME, which happened here at the University of Tubingen and led to the work the company does today. A pivotal trial for a cell therapy in melanoma will trigger an analysis this year, and Immatics also has bispecific programs and a second generation cell therapy under development.

Co-Founder & CEO Cameron Pye walks us through the science of macrocyclic peptides, and discusses the for partnerships (BridgeBio, argenx, Merck, and Novartis). The company raised a $45M series B in March.

Philip Astley-Sparke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.

CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases. Chapters His career - 0:00 A monoclonal approach - 1:50 Measles - 7:28 The science behind Invivyd - 11:10 Pandemic preparedness - 19:24 Advice to students - 20:50

Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such a system could also improve a patient's rehab and might potentially have further uses in diseases of cognitive decline.

Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a single instrument, scaling to thousands of samples per year for targeted assays, and has single-cell level sensitivity.

After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach targeting urea cycle disorders, hepatic encephalopathy, and new alpha-1 program. The company recently closed a $85 private placement. Coverage brought to you by

He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy. Coverage brought to you by

He reminds us of the unmet need for this type of therapy and discusses the planning that Vera has been doing ahead of the decision date. Coverage brought to you by

He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement inhibitor from Q32 Bio. Coverage brought to you by

He discusses the INHBE data and the market reaction to it, which he believes is due to misconceptions about the patient population, and the next steps for this program. Plus, an AATD presentation that will happen next month at American Thoracic Society. Coverage brought to you by

CEO Alise Reicin walks us through recent data and guides for what is next in this patient population. Plus, an upcoming healthily volunteer readout for a HHT program and how it might translate to patients in future trials. Coverage brought to you by

CEO James Helliwell describes Euprexia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and how the company thinks about other uses. Coverage brought to you by

Co-Founder and CEO Jeffrey Finer describes how Septerna is able to screen for GPCR targets in ways that have not previously been possible. Plus, an overview of programs targeting MRGPRX2, PTH1R, and a collaboration with Novo on obesity. Coverage brought to you by

CEO Ajit Singh describes the idea behind the new products, and highlights that $100M has been raised to fund the development of them.

CEO Cameron Turtle walks us through the data, shares his opinion on its translatability to part B of the current study, and tells us what else is ahead for Spyre.